Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25366335 | 0.80 | ADORA2A (0.46) | ADORA2AADORA2BJAK2ALDH1A1TSHR | |
| SCHEMBL31147782 | 0.80 | ADORA2A (0.46) | ADORA2AADORA2BJAK2ALDH1A1TSHR | |
| SCHEMBL22889757 | 0.77 | CHEK1 (0.35) | JAK2ALDH1A1TSHRGAACYP1A2 | |
| SCHEMBL2861121 | 0.73 | ADORA2A (0.43) | ADORA2AADORA2BGAA | |
| SCHEMBL25367250 | 0.72 | ADORA2A (0.46) | ADORA2AADORA2BALDH1A1TSHR | |
| SCHEMBL25366793 | 0.72 | — | — | |
| SCHEMBL20110646 | 0.70 | ADORA2A (0.41) | ADORA2AADORA2BALDH1A1TSHRPOLB | |
| SCHEMBL22890550 | 0.67 | NTRK1 (0.40) | ADORA2A | |
| SCHEMBL7571499 | 0.67 | GSK3B (0.51) | JAK2ALDH1A1GAACYP3A4MAPT | |
| SCHEMBL29644051 | 0.67 | GSK3B (0.51) | JAK2ALDH1A1GAACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | ADORA2A 125/4885ADORA2B 154/4885JAK2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.